Project description
Improving multimorbidity treatment with a pre-commercial procurement-based approach
Multimorbidity is increasing, driven by the ageing population. In Europe, tens of millions of people suffer from multimorbidity. There is an urgent need for technology that enables specific care, treatment, administration and support. The EU-funded Carematrix PCP project will develop innovative technology that allows for more holistic, predictive care and support benefits. It will develop this in close dialogue with patients, care providers and industry sectors, in line with an approach based on pre-commercial procurement that includes co-creation processes, contract management, evaluation and testing, as well as business development support. The project’s goal is to shorten time spent in care facilities, reduce clinical errors and increase patient safety.
Objective
Over 50m people suffer from multimorbidity (PMM) in Europe. Recent reviews find that PMM experience a range of system and professional-related issues with care delivery. In part, this is because current investments in process-based delivery means delivering healthcare within single diagnoses tracks/silos. For PMMs this does not reflect real-world conditions.
No technology is available today that enables the specific care, treatment, administration and support needed for this target group. Breakthrough solutions will classify the individual according to their co/multimorbidities and medications. But this needs to be developed in close dialogue between PMM, care providers and industry sectors based upon a strong demand driven approach in a PCP.
Accordingly, the CareMatrix Buyers Group (SE, NO, ES) challenge the market to develop innovative technology that enables more predictive care and support benefits for PMM. This is achieved with 6 project objectives summarised as PCP: stakeholder engagement, roadmap, Call, implementation, next steps and; profiling and outreach via IFIC.
The methodology can be summarised as PCP: framing actions (PCP preparation, use of UCD principles and practice); implementation actions (Phases 1-3 contract management, support, evaluation and testing) and Market Preparation actions (business development support for Phase 3 suppliers, standards, initial PPI preparation).
Direct benefits include:
• 20% reduction in time spent for visits to care facilities
• Improvements from baseline in at least 75% of aspects of care as identified using PREM surveys
• 50% fewer patient data-related incidents (increased patient safety) between organizations
• No of clinical errors reduced by 30%;
Underpinning the CareMatrix solution(s) with integrated innovation (supportive policy priorities, organisational and social innovations) will optimise the potential of those solutions to produce savings of 10% in health care expenditure for PMM.
Fields of science
Programme(s)
Funding Scheme
PCP - Pre-Commercial ProcurementCoordinator
223 81 Lund
Sweden